Christopher Thomas Giordano
CEO at Tenax Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2024
3 years of board service in total across 1 board, counting each seat separately. Longest: Tenax Therapeutics Inc., 2 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Tenax Therapeutics Inc. June 2, 202699.0%
-
Tenax Therapeutics Inc. June 11, 202599.4%
-
Tenax Therapeutics Inc. June 7, 202481.8%
-
Tenax Therapeutics Inc. June 9, 202378.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Tenax Therapeutics Inc. | Open-market purchase | +4,850 | $1.82 | $8,827 |
| Sep 11, 2026 | Tenax Therapeutics Inc. | Open-market purchase | +6,000 | $1.88 | $11,280 |
| Jul 13, 2026 | Tenax Therapeutics Inc. | Option exercise | +219 | $3.55 | $777 |
| Jul 13, 2026 | Tenax Therapeutics Inc. | Option exercise | +8,500 | $5.94 | $50,490 |
| Nov 20, 2025 | Tenax Therapeutics Inc. | Open-market purchase | +538 | $7.59 | $4,083 |
| Nov 19, 2025 | Tenax Therapeutics Inc. | Open-market purchase | +455 | $7.51 | $3,417 |
| Nov 18, 2025 | Tenax Therapeutics Inc. | Open-market purchase | +1,612 | $7.75 | $12,493 |
Questions about Christopher Thomas Giordano
What boards is Christopher Thomas Giordano on?
Christopher Thomas Giordano sits on the board of Tenax Therapeutics Inc.
What company is Christopher Thomas Giordano the CEO of?
Christopher Thomas Giordano is CEO of Tenax Therapeutics Inc.
How long has Christopher Thomas Giordano served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.